Vanessa Research, Inc. (VRI), an emerging healthcare and biotech company, announced today that it filed a patent for a novel therapy to neutralize the lethal diarrhea induced by the cholera toxin.
VRI has been developing treatments that address lethal secretory diarrheal diseases under the direction of Dr. Dmitry Kravtsov, VP of Research and Development. “Addressing cholera supports Vanessa’s overall mission of giving hope where none exists,” said Dr. Kravtsov.
According to the World Health Organization, cholera is an acute diarrheal infection that remains a global threat to public health and an indicator of inequity and lack of social development. Researchers have estimated that every year, there are roughly 1.3 to 4.0 million cases, and 21,000 to 143,000 deaths worldwide due to cholera.1
This patent represents an expansion of VRI’s portfolio of anti-diarrheal drugs. VRI’s first product Shylicine™, a treatment for a rare pediatric disease known as microvillus inclusion disease, received its patent in 2017.
About Vanessa Research
Vanessa Research is based in Hamden, Connecticut, with offices in London and Budapest. VRI was founded on the desire to build a 21st century, sustainable, innovative, entrepreneurial organization by bringing together a collection of diverse scientists, engineers, business professionals and academics to create solutions in medicine.
The company’s mission is to “give hope where none existed”™ by delivering healthcare products that improve and increase access to quality care while decreasing costs.
Marketing and Communication
Vanessa Research, Inc.
925 Sherman Avenue,
Hamden, CT, 06514 U.S.A.
1Updated global burden of cholera in endemic countries. Ali M, Nelson AR, Lopez AL, Sack D. (2015). PLoS Negl Trop Dis
9(6): e0003832. doi:10.1371/journal.pntd.0003832.
Shylicine and “give hope where none existed” are trademarks and copyrights of Vanessa Research, Inc.